Five Prime begins Phase I/II trial of FPA008 to treat pigmented villonodular synovitis
FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R) and it targets macrophages and monocytes, which are activated or elevated in multiple disease settings. Five Prime
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.